Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer

Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer

The detection of prostate cancer lesions by PET imaging of the prostate-specific membrane antigen (PSMA) has gained highest clinical impact during the last years. 68Ga-labelled Glu-urea-Lys(Ahx)-HBED-CC ([68Ga]Ga-PSMA-HBED-CC) represents a successful novel PSMA inhibitor radiotracer which has recen...

Full description

Bibliographic Details
Main Authors: Matthias Eder, Oliver Neels, Miriam Müller, Ulrike Bauder-Wüst, Yvonne Remde, Martin Schäfer, Ute Hennrich, Michael Eisenhut, Ali Afshar-Oromieh, Uwe Haberkorn, Klaus Kopka
Format: Article
Language:English
Published: MDPI AG 2014-06-01
Series:Pharmaceuticals
Subjects:
68Ga-PET imaging
PSMA
HBED-CC
prostate cancer
radiopharmaceutical production
good manufacturing practice
GMP
Online Access:http://www.mdpi.com/1424-8247/7/7/779

Internet

http://www.mdpi.com/1424-8247/7/7/779

Similar Items